RVU120 is a medication being studied for its potential to treat certain types of blood cancers, specifically high-risk myelodysplastic syndrome and acute myeloid leukemia. These are conditions where the bone marrow does not produce enough healthy blood cells. RVU120 is being tested to see if it can help reduce or eliminate cancer cells in patients who have not responded to other treatments or whose cancer has returned. The trial is also looking at how well RVU120 works in patients with a specific genetic mutation known as NPM1. This medication is given on its own, without being combined with other cancer treatments, to see how effective it is by itself.

Acute Myeloid Leukemia with or without NPM1 Mutation – Acute Myeloid Leukemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow and quickly progresses to affect the blood. It is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. The disease can lead to symptoms such as fatigue, frequent infections, and easy bruising or bleeding. The presence or absence of the NPM1 mutation can influence the behavior of the leukemia cells. AML progresses rapidly and requires prompt medical attention to manage its effects on the body.

Relapsed or Refractory High-Risk Myelodysplastic Syndrome – Myelodysplastic Syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells. In high-risk MDS, the bone marrow does not produce enough healthy blood cells, leading to anemia, infections, and bleeding problems. When MDS is relapsed, it means the disease has returned after treatment, and refractory MDS does not respond to standard treatments. The disease can progress to acute leukemia if not managed. High-risk MDS is characterized by a higher likelihood of progression and more severe symptoms compared to lower-risk forms.